Regeneron Pharmaceuticals REGN
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Regeneron Pharmaceuticals (REGN) Core Market Data and Business Metrics
Latest Closing Price
$617Price-Earnings Ratio
16.09Total Outstanding Shares
107.51 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
777 Old Saw Mill River Road, Tarrytown, NY, 10591
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,030,984 Shares | 3.15 | 3/14/2025 | 3,249,157 Shares |
| 778,843 Shares | 3.29 | 2/28/2025 | 2,565,723 Shares |
| 1,068,824 Shares | 2.06 | 2/14/2025 | 2,204,900 Shares |
| 913,424 Shares | 2.4 | 1/31/2025 | 2,187,734 Shares |
| 834,775 Shares | 2.54 | 1/15/2025 | 2,117,354 Shares |
| 852,546 Shares | 2.46 | 12/31/2024 | 2,095,552 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $-700,000 |
| Net Cash Flow From Operating Activities, Continuing | $4.42 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-2.20 Billion |
| Net Cash Flow From Financing Activities | $-2.20 Billion |
| Net Cash Flow, Continuing | $-248.10 Million |
| Net Cash Flow | $-248.80 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $4.41 Billion |
| Income Tax Expense/Benefit, Deferred | $-757.30 Million |
| Net Income/Loss Attributable To Parent | $4.41 Billion |
| Nonoperating Income/Loss | $789.20 Million |
| Basic Earnings Per Share | $40.90 |
| Operating Income/Loss | $3.99 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $4.49 Billion |
| Comprehensive Income/Loss | $4.49 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $73 Million |
| Comprehensive Income/Loss Attributable To Parent | $4.49 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Assets | $37.76 Billion |
| Other Non-current Assets | $17.95 Billion |
| Accounts Payable | $789.50 Million |
| Other Current Assets | $15.57 Billion |
| Liabilities And Equity | $37.76 Billion |
| Current Assets | $18.66 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||